Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Vazyme Biotech Co's Total Liabilities for the quarter that ended in Mar. 2026 was ¥1,308 Mil.
Nanjing Vazyme Biotech Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥1,165.65 Mil) to Dec. 2025 (¥1,236.73 Mil) and
increased
from Dec. 2025 (¥1,236.73 Mil) to Mar. 2026 (¥1,308.21 Mil).
Nanjing Vazyme Biotech Co's annual Total Liabilities
declined
from Dec. 2023 (¥1,716.89 Mil) to Dec. 2024 (¥1,105.05 Mil) but then
increased
from Dec. 2024 (¥1,105.05 Mil) to Dec. 2025 (¥1,236.73 Mil).
Nanjing Vazyme Biotech Co Total Liabilities Related Terms
Nanjing Vazyme Biotech Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vazyme Biotech Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Nanjing Vazyme Biotech Co's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vazyme Biotech Co (SHSE:688105) has a Total Liabilities of ¥1,308 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanjing Vazyme Biotech Co and its competitors.
Is Nanjing Vazyme Biotech Co's Total Liabilities too high?
Nanjing Vazyme Biotech Co's current Total Liabilities is ¥1,308 Mil. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's Total Liabilities compare to VRTX and REGN?
Nanjing Vazyme Biotech Co's Total Liabilities of ¥1,308 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanjing Vazyme Biotech Co and its competitors. Nanjing Vazyme Biotech Co's current Total Liabilities is ¥1,308 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Fairly Valued. The stock's GF Value™ is ¥17.73, compared to a current price of ¥16.88 — trading 4.8% below its estimated fair value. The current Total Liabilities is ¥1,308 Mil. Nanjing Vazyme Biotech Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current Total Liabilities is ¥1,308 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be undervalued.
The current stock price of ¥16.88 is trading 4.8% below its estimated GF Value™ of ¥17.73.
GuruFocus considers Nanjing Vazyme Biotech Co to be Fairly Valued.
Key valuation signals for SHSE:688105:
Total Liabilities: ¥1,308 Mil
GF Value™: ¥17.73 vs. price of ¥16.88 (4.8% below fair value)
No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressKechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
73GF Score
Get the complete analysis for SHSE:688105
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688105 has been successfully added to your 
